Using disease-modifying therapies in sickle cell disease

2.

Piel

FB

,

Patil

AP

,

Howes

RE

, et al.

Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates

.

Lancet

.

2013

;

381

(

9861

):

142

-

151

.

doi:10.1016/S0140-6736(12)61229-X

.

3.

Ranque

B

,

Kitenge

R

,

Ndiaye

DD

, et al.

Estimating the risk of child mortality attributable to sickle cell anaemia in sub-Saharan Africa: a retrospective, multicentre, case-control study

.

Lancet Haematol

.

2022

;

9

(

3

):

e208

-

e216

.

doi:10.1016/S2352-3026(22)00004-7

.

4.

Telfer

P

,

Coen

P

,

Chakravorty

S

, et al.

Clinical outcomes in children with sickle cell disease living in England: a neonatal cohort in East London

.

Haematologica

.

2007

;

92

(

7

):

905

-

912

.

doi:10.3324/haematol.10937

.

5.

Platt

OS

,

Brambilla

DJ

,

Rosse

WF

, et al.

Mortality in sickle cell disease. Life expectancy and risk factors for early death

.

N Engl J Med

.

1994

;

330

(

23

):

1639

-

1644

.

doi:10.1056/NEJM199406093302303

.

6.

Elmariah

H

,

Garrett

ME

,

De Castro

LM

, et al.

Factors associated with survival in a contemporary adult sickle cell disease cohort

.

Am J Hematol

.

2014

;

89

(

5

):

530

-

535

.

doi:10.1002/ajh.23683

.

7.

Maitra

P

,

Caughey

M

,

Robinson

L

, et al.

Risk factors for mortality in adult patients with sickle cell disease: a meta-analysis of studies in North America and Europe

.

Haematologica

.

2017

;

102

(

4

):

626

-

636

.

doi:10.3324/haematol.2016.153791

.

8.

DeBaun

MR

,

Ghafuri

DL

,

Rodeghier

M

, et al.

Decreased median survival of adults with sickle cell disease after adjusting for left truncation bias: a pooled analysis

.

Blood

.

2019

;

133

(

6

):

615

-

617

.

doi:10.1182/blood-2018-10-880575

.

9.

Bunn

HF

.

Pathogenesis and treatment of sickle cell disease

.

N Engl J Med

.

1997

;

337

(

11

):

762

-

769

.

doi:10.1056/NEJM199709113371107

.

10.

Kato

GJ

,

Gladwin

MT

,

Steinberg

MH

.

Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes

.

Blood Rev

.

2007

;

21

(

1

):

37

-

47

.

doi:10.1016/j.blre.2006.07.001

.

11.

Kato

GJ

,

Piel

FB

,

Reid

CD

, et al.

Sickle cell disease

.

Nat Rev Dis Primers

.

2018

;

15

(

4

):

18010

.

doi:10.1038/nrdp.2018.10

.

12.

Eaton

WA

,

Bunn

HF

.

Treating sickle cell disease by targeting HbS polymerization

.

Blood

.

2017

;

129

(

20

):

2719

-

2726

.

doi:10.1182/blood-2017-02-765891

.

13.

Charache

S

,

Terrin

ML

,

Moore

RD

, et al;

Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia

.

Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia

.

N Engl J Med

.

1995

;

332

(

20

):

1317

-

1322

.

doi:10.1056/NEJM199505183322001

.

14.

Wang

WC

,

Ware

RE

,

Miller

ST

, et al;

BABY HUG Investigators

.

Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)

.

Lancet

.

2011

;

377

(

9778

):

1663

-

1672

.

doi:10.1016/S0140-6736(11)60355-3

.

15.

Yawn

BP

,

Buchanan

GR

,

Afenyi-Annan

AN

, et al.

Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members

.

JAMA

.

2014

;

312

(

10

):

1033

-

1048

.

doi:10.1001/jama.2014.10517

.

16.

de Montalembert

M

,

Voskaridou

E

,

Oevermann

L

, et al;

All ESCORT HU Investigators

.

Real-life experience with hydroxyurea in patients with sickle cell disease: results from the prospective ESCORT-HU cohort study

.

Am J Hematol

.

2021

;

96

(

10

):

1223

-

1231

.

doi:10.1002/ajh.26286

.

17.

Hankins

JS

,

McCarville

MB

,

Rankine-Mullings

A

, et al.

Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: a phase III international randomized clinical trial

.

Am J Hematol

.

2015

;

90

(

12

):

1099

-

1105

.

doi:10.1002/ajh.24198

.

18.

Ware

RE

,

Davis

BR

,

Schultz

WH

, et al.

Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD with transfusions changing to hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial

.

Lancet

.

2016

;

387

(

10019

):

661

-

670

.

doi:10.1016/S0140-6736(15)01041-7

.

19.

Tshilolo

L

,

Tomlinson

G

,

Williams

TN

, et al;

REACH Investigators

.

Hydroxyurea for children with sickle cell anemia in Sub-Saharan Africa

.

N Engl J Med

.

2019

;

380

(

2

):

121

-

131

.

doi:10.1056/NEJMoa1813598

.

20.

Abdullahi

SU

,

Jibir

BW

,

Bello-Manga

H

, et al.

Hydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (SPRING): a double-blind, multicentre, randomised, phase 3 trial

.

Lancet Haematol

.

2022

;

9

(

1

):

e26

-

e37

.

doi:10.1016/S2352-3026(21)00368-9

.

21.

DeBaun

MR

,

Jordan

LC

,

King

AA

, et al.

American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults

.

Blood Adv

.

2020

;

4

(

8

):

1554

-

1588

.

doi:10.1182/bloodadvances.2019001142

.

22.

Oksenberg

D

,

Dufu

K

,

Patel

MP

, et al.

GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease

.

Br J Haematol

.

2016

;

175

(

1

):

141

-

153

.

doi:10.1111/bjh.14214

.

23.

Vichinsky

E

,

Hoppe

CC

,

Ataga

KI

, et al;

HOPE Trial Investigators

.

A phase 3 randomized trial of voxelotor in sickle cell disease

.

N Engl J Med

.

2019

;

381

(

6

):

509

-

519

.

doi:10.1056/NEJMoa1903212

.

24.

Estepp

JH

,

Kalpatthi

R

,

Woods

G

, et al.

Safety and efficacy of voxelotor in pediatric patients with sickle cell disease aged 4 to 11 years

.

Pediatr Blood Cancer

.

2022

;

69

(

8

):

e29716

.

doi:10.1002/pbc.29716

.

25.

Ataga

KI

,

Reid

M

,

Ballas

SK

, et al;

ICA-17043-10 Study Investigators

.

Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043)

.

Br J Haematol

.

2011

;

153

(

1

):

92

-

104

.

doi:10.1111/j.1365-2141.2010.08520.x

.

26.

Brousseau

DC

,

Scott

JP

,

Badaki-Makun

O

, et al;

Pediatric Emergency Care Applied Research Network (PECARN)

.

A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children

.

Blood

.

2015

;

126

(

14

):

1651

-

1657

.

doi:10.1182/blood-2015-05-647107

.

27.

Niihara

Y

,

Miller

ST

,

Kanter

J

, et al;

Investigators of the phase 3 trial of l-glutamine in sickle cell disease

.

A phase 3 trial of l-glutamine in sickle cell disease

.

N Engl J Med

.

2018

;

379

(

3

):

226

-

235

.

doi:10.1056/NEJMoa1715971

.

28.

Sins

JWR

,

Fijnvandraat

K

,

Rijneveld

AW

, et al.

Effect of N-acetylcysteine on pain in daily life in patients with sickle cell disease: a randomised clinical trial

.

Br J Haematol

.

2018

;

182

(

3

):

444

-

448

.

doi:10.1111/bjh.14809

.

29.

Ataga

KI

,

Kutlar

A

,

Kanter

J

, et al.

Crizanlizumab for the prevention of pain crises in sickle cell disease

.

N Engl J Med

.

2017

;

376

(

5

):

429

-

439

.

doi:10.1056/NEJMoa1611770

.

30.

Novartis

AG

.

Novartis provides update on Phase III STAND trial assessing crizanlizumab

. https://www.novartis.com/news/novartis-provides-update-phase-iii-stand-trial-assessing-crizanlizumab. Accessed

9

October

2023

.

31.

Telen

MJ

,

Wun

T

,

McCavit

TL

, et al.

Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use

.

Blood

.

2015

;

125

(

17

):

2656

-

2664

.

doi:10.1182/blood-2014-06-583351

.

32.

Dampier

CD

,

Telen

MJ

,

Wun

T

, et al;

RESET Investigators

.

A randomized clinical trial of the efficacy and safety of rivipansel for sickle cell vaso-occlusive crisis

.

Blood

.

2023

;

141

(

2

):

168

-

179

.

doi:10.1182/blood.2022015797

.

33.

Biemond

BJ

,

Tombak

A

,

Kilinc

Y

, et al.

Efficacy and safety of sevuparin, a novel non-anti-coagulant heparinoid, in patients with acute painful vaso-occlusive crisis; a global, multicenter double-blind, randomized, placebo controlled phase-2 trial (TVOCO1)

.

Blood

.

2019

;

134

(

suppl 1

):

614

.

doi:10.1182/blood-2019-124653

.

34.

Orringer

EP

,

Casella

JF

,

Ataga

KI

, et al.

Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: a randomized controlled trial

.

JAMA

.

2001

;

286

(

17

):

2099

-

2106

.

doi:10.1001/jama.286.17.2099

.

35.

Casella

JF

,

Kronsberg

SS

,

Gorney

RT

.

Poloxamer 188 vs placebo for painful vaso-occlusive episodes in children and adults with sickle cell disease-reply

.

JAMA

.

2021

;

326

(

10

):

975

-

976

.

doi:10.1001/jama.2021.11103

.

36.

Hebbel

RP

,

Osarogiagbon

R

,

Kaul

D.

The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy

.

Microcirculation

.

2004

;

11

(

2

):

129

-

151

.

doi:10.1080/10739680490278402

.

37.

Field

JJ

,

Majerus

E

,

Gordeuk

VR

, et al.

Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease

.

Blood Adv

.

2017

;

1

(

20

):

1645

-

1649

.

doi:10.1182/bloodadvances.2017009613

.

38.

Daak

AA

,

Dampier

CD

,

Fuh

B

, et al.

Double-blind, randomized, multicenter phase 2 study of SC411 in children with sickle cell disease (SCOT trial)

.

Blood Adv

.

2018

;

2

(

15

):

1969

-

1979

.

doi:10.1182/bloodadvances.2018021444

.

39.

Rees

DC

,

Kilinc

Y

,

Unal

S

, et al.

A randomized, placebo-controlled, double-blind trial of canakinumab in children and young adults with sickle cell anemia

.

Blood

.

2022

;

139

(

17

):

2642

-

2652

.

doi:10.1182/blood.2021013674

.

40.

Field

JJ

,

Kassim

A

,

Brandow

A

, et al.

Phase 2 trial of montelukast for prevention of pain in sickle cell disease

.

Blood Adv

.

2020

;

4

(

6

):

1159

-

1165

.

doi:10.1182/bloodadvances.2019001165

.

41.

Gladwin

MT

,

Kato

GJ

,

Weiner

D

, et al;

DeNOVO Investigators

.

Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial

.

JAMA

.

2011

;

305

(

9

):

893

-

902

.

doi:10.1001/jama.2011.235

.

42.

Maitre

B

,

Djibre

M

,

Katsahian

S

, et al.

Inhaled nitric oxide for acute chest syndrome in adult sickle cell patients: a randomized controlled study

.

Intensive Care Med

.

2015

;

41

(

12

):

2121

-

2129

.

doi:10.1007/s00134-015-4060-2

.

43.

Onalo

R

,

Cooper

P

,

Cilliers

A

, et al.

Randomized control trial of oral arginine therapy for children with sickle cell anemia hospitalized for pain in Nigeria

.

Am J Hematol

.

2021

;

96

(

1

):

89

-

97

.

doi:10.1002/ajh.26028

.

44.

Machado

RF

,

Barst

RJ

,

Yovetich

NA

, et al;

walk-PHaSST Investigators and Patients

.

Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity

.

Blood

.

2011

;

118

(

4

):

855

-

864

.

doi:10.1182/blood-2010-09-306167

.

45.

Beurling-Harbury

C

,

Schade

SG

.

Platelet activation during pain crisis in sickle cell anemia patients

.

Am J Hematol

.

1989

;

31

(

4

):

237

-

241

.

doi:10.1002/ajh.2830310404

.

46.

Inwald

DP

,

Kirkham

FJ

,

Peters

MJ

, et al.

Platelet and leucocyte activation in childhood sickle cell disease: association with nocturnal hypoxaemia

.

Br J Haematol

.

2000

;

111

(

2

):

474

-

481

.

doi:10.1046/j.1365-2141.2000.02353.x

.

47.

Jakubowski

JA

,

Zhou

C

,

Jurcevic

S

, et al.

A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation

.

Thromb Res

.

2014

;

133

(

2

):

190

-

195

.

doi:10.1016/j.thromres.2013.12.008

.

48.

Lee

SP

,

Ataga

KI

,

Orringer

EP

,

Phillips

DR

,

Parise

LV

.

Biologically active CD40 ligand is elevated in sickle cell anemia: potential role for platelet-mediated inflammation

.

Arterioscler Thromb Vasc Biol

.

2006

;

26

(

7

):

1626

-

1631

.

doi:10.1161/01.atv.0000220374.00602.a2

.

49.

Wun

T

,

Paglieroni

T

,

Rangaswami

A

, et al.

Platelet activation in patients with sickle cell disease

.

Br J Haematol

.

1998

;

100

(

4

):

741

-

749

.

doi:10.1046/j.1365-2141.1998.00627.x

.

50.

Cabannes

R

,

Lonsdorfer

J

,

Castaigne

JP

,

Ondo

A

,

Plassard

A

,

Zohoun

I.

Clinical and biological double-blind-study of ticlopidine in preventive treatment of sickle-cell disease crises

.

Agents Actions Suppl

.

1984

;

15

:

199

-

212

. PMID: 6385647

.

51.

Heeney

MM

,

Hoppe

CC

,

Abboud

MR

, et al;

DOVE Investigators

.

A multinational trial of prasugrel for sickle cell vaso-occlusive events

.

N Engl J Med

.

2016

;

374

(

7

):

625

-

635

.

doi:10.1056/NEJMoa1512021

.

52.

Heeney

MM

,

Abboud

MR

,

Githanga

J

, et al.

Ticagrelor vs placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 study

.

Blood

.

2022

;

140

(

13

):

1470

-

1481

.

doi:10.1182/blood.2021014095

.

53.

Qari

MH

,

Aljaouni

SK

,

Alardawi

MS

, et al.

Reduction of painful vaso- occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial

.

Thromb Haemost

.

2007

;

98

(

08

):

392

-

396

.

doi:10.1160/th06-12-0718

.

54.

Anderson

A

,

El Rassi

F

,

DeBaun

MR

, et al.

Interim analysis of a phase 2 trial to assess the efficacy and safety of crizanlizumab in sickle cell disease patients with priapism (SPARTAN)

.

Blood

.

2022

;

140

(

suppl 1

):

1636

-

1638

.

doi:10.1182/blood-2022-157004

.

55.

Kanter

J

,

Brown

RC

,

Norris

C

, et al.

Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease

.

Blood Adv

.

2023

;

7

(

6

):

943

-

952

.

doi:10.1182/bloodadvances.2022008209

.

56.

Matthew

MH

,

Rees

DC

,

De Montalembert

M

, et al.

Initial safety and efficacy results from the phase II, multicenter, open-label solace-kids trial of crizanlizumab in adolescents with sickle cell disease (SCD)

.

Blood

.

2021

;

138

(

suppl 1

):

12

.

doi:10.1182/blood-2021-144730

.

57.

Benjamin

LJ

,

Berkowitz

LR

,

Orringer

E

, et al.

A collaborative, double-blind randomized study of cetiedil citrate in sickle cell crisis

.

Blood

.

1986

;

67

(

5

):

1442

-

1447

.

doi:10.1182/blood.v67.5.1442.bloodjournal6751442

.

58.

Gillette

PN

,

Peterson

CM

,

Lu

YS

,

Cerami

A.

Sodium cyanate as a potential treatment for sickle-cell disease

.

N Engl J Med

.

1974

;

290

(

12

):

654

-

660

.

doi:10.1056/NEJM197403212901204

.

59.

Griffin

TC

,

McIntire

D

,

Buchanan

GR

.

High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease

.

N Engl J Med

.

1994

;

330

(

11

):

733

-

737

.

doi:10.1056/nejm199403173301101

.

60.

Weiner

DL

,

Hibberd

PL

,

Betit

P

,

Cooper

AB

,

Botelho

CA

,

Brugnara

C.

Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in pediatric patients with sickle cell disease

.

JAMA

.

2003

;

289

(

9

):

1136

.

doi:10.1001/jama.289.9.1136

.

61.

Morris

CR

,

Kuypers

FA

,

Lavrisha

L

, et al.

A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes

.

Haematologica

.

2013

;

98

(

9

):

1375

-

1382

.

doi:10.3324/haematol.2013.086637

.

62.

Rai

P

,

Ataga

KI

.

Drug therapies for the management of sickle cell disease

.

F1000Res

.

2020

Jun

11

;

9

:

F1000

Faculty Rev-592. eCollection 2020.

PMID: 32765834

.

doi.org/10.12688/f1000research.22433.1

.